FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to ...

Antimicrobial resistance and ecological disruption caused by broad-spectrum disinfectants have created an urgent need for ...

As mentioned earlier, there is an urgent need for the development of novel antibiotics targeting S. aureus. Fortunately, a number of new agents active against MRSA and other Gram-positive pathogens ...

Detailed price information for Armata Pharmaceuticals Inc (ARMP-A) from The Globe and Mail including charting and trades.

Armata Pharmaceuticals, Inc. ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the ...

Bacteria from cows has shown "promising" results in treating hospital superbugs. The farmyard favorites carry a microbe that ...

Scientists have discovered 13 new bacteria species in unique foods and environments that could transform health and the environment.

Researchers have developed a sunlight-activated nanospray that can rapidly kill drug-resistant bacteria, stop bleeding and relieve pain, significantly accelerating the healing of infected diabetic ...

Experts warn that antibiotic misuse is fueling drug-resistant infections like gonorrhoea and staph, making them harder to ...

A new study reveals over 70% of staph infections in Nigeria are resistant to common antibiotics, a major public health ...

The African health organisation said that the study analysed more than 187,000 laboratory test results from 205 laboratories in 14 African countries, including Nigeria.

Clinical portfolio strengthened through the in-licensing of phase 3-ready antibiotic ceftibuten-ledaborbactam Fosmanogepix second phase 3 study ...